Advanced Filters
noise

Lyon Cedex 03, France Clinical Trials

A listing of Lyon Cedex 03, France clinical trials actively recruiting patients volunteers.

Found 737 clinical trials
P Pierre Saintigny, MD-PhD

Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients

As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing. The SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on …

years of age All Phase N/A
P Patricia FRANCO, Pr

Sleep Disorders in Specific Learning Disabilities

Specific learning disorders, or SLD, are cognitive and behavioral conditions that emerge during childhood and involve significant difficulties in acquiring and performing specific intellectual, motor, language, and social functions. These disorders impact personal, social, academic, and professional functioning throughout life. In France, between 6% and 8% of the population, including …

4 years of age All Phase N/A
S Sandra VUKUSIC, MD

French Registry for Monitoring Pregnancies for Multiple Sclerosis

The influence of pregnancy on the course of multiple sclerosis (MS) has long been a controversial topic. After the publication of the first large prospective study of pregnancy and MS in 1998, counselling of women with MS has radically changed and many patients have been able to fulfill their desire …

years of age All Phase N/A
A Aurélie Affret, PhD

LISA Post Market Clinical Follow-Up Study: Documentation of Clinical Outcomes After Surgery With LISA Implant

The study is a post-market surveillance study of the Lumbar Implant for Stiffness Augmentation (LISA), a medical device, which is used to treat low-back pain that accompanies degenerative lesions of grades II, III, and IV (Pfirrmann MRI classification). "Post-market" means the device (i.e. the LISA implant) being used in this …

18 years of age All Phase N/A
A Andoni LAGUNA, MD

Immunoglobulin M (IgM)-Anti-myelin-associated-glycoprotein(MAG) Peripheral Neuropathy Study

There is no international consensus regarding how to assess and treat patients with immunoglobulin M (IgM)-anti-myelin-associated-glycoprotein (MAG) monoclonal gammopathy associated peripheral neuropathy. The purpose of the IMAGiNe study-Lyon/Bicêtre is to prospectively collect standardized clinical data of 25 patients with IgM-anti-MAG monoclonal gammopathy associated peripheral neuropathy in order to participate in …

18 years of age All Phase N/A
P Philippe Descamps, Pr

Interest of Salivary Signature of Endometriosis in the Heathcare Pathway of Adolescent

ADOmiARN is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in obstetrics, gynecology and pediatrics departments in France and in Belgium. The main objective is to confirm the interest of the in vitro diagnostic medical device (EndoTest®) in adolescents with suspected endometriosis. The study population is made up of …

10 - 19 years of age Female Phase N/A
L Louis CHAUVELOT, MD

Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections

Type I interferons (IFN-I) production is induced by the detection of viral molecules, such as RNA or DNA viral strands, through pattern recognition receptors (PRR) present on many immune cell types. Despite a minimal concentration, IFN-I secretion activate the secretion, by neighbouring cells, of more than 700 proteins with antiviral …

years of age All Phase N/A
L Laurent VILLENEUVE

A Research Registry on Aggressive PitNETs

To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. The multidisciplinary consultation meeting (RCP), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (HYPOcare), which is …

18 years of age All Phase N/A
C Catherine RIOUFOL, Pharm. D

Quality Of Life and Drug Use in Patients With CAR-T Cells

CAR-T cells are a major therapeutic innovation in the management of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in 3rd line or more. Kymriah® and Yescarta® are the first CAR-T with Marketing Authorization and coverage by the French Health Insurance. Their clinical interest has been demonstrated …

18 years of age All Phase N/A
N Nacer Mansouri, Doctor

Safety and Performance of the Hexanium TLIF System in the Treatment of Degenerative Disc Disease

The goal of this observational study is to confirm the safety and efficacy of the Hexanium TLIF system in the treatment of skeletally mature patients suffering from degenerative disc disease (disease that occurs when the spinal disk break down). Part of their standard of care, participants will be questioned on …

18 years of age All Phase N/A

Simplify language using AI